SCM
FPRX

Segantii Capital Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Segantii Capital Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-500
Closed -$18K – 325
2017
Q1 		$18K Buy
+500
New +$22K ﹤0.01% 361

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Segantii Capital Management's FPRX Position: Q2 2017 in Review

Segantii Capital Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2017, closing a stake of 500 shares — an estimated $18K sold.

Segantii Capital Management first reported a position in FPRX in Q1 2017 and held it in 1 quarter. The position peaked at $18K in Q1 2017. 123 funds tracked by Wall St. Rank hold FPRX as of Q2 2017.

  • Segantii Capital Management reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Segantii Capital Management sold 500 Five Prime Therapeutics, Inc. shares in Q2 2017, an estimated $18K.
  • Segantii Capital Management first reported a position in Five Prime Therapeutics, Inc. in Q1 2017 and held it in 1 quarter.
  • Segantii Capital Management's Five Prime Therapeutics, Inc. position peaked at $18K in Q1 2017.
  • 123 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2017.

Based on Segantii Capital Management's 13F filing for Q2 2017, filed 2 Aug 2017.